We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Targacept Announces Designation of Lead Compound in Smoking Cessation Program
News

Targacept Announces Designation of Lead Compound in Smoking Cessation Program

Targacept Announces Designation of Lead Compound in Smoking Cessation Program
News

Targacept Announces Designation of Lead Compound in Smoking Cessation Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Targacept Announces Designation of Lead Compound in Smoking Cessation Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Targacept, Inc. has announced the designation of a lead compound in its smoking cessation program, triggering a $500,000 milestone payment under its alliance agreement with GlaxoSmithKline (GSK).

“We are delighted to have successfully leveraged our expertise in NNRs to bring forward a novel compound for smoking cessation, an area that is not only a major healthcare need but also where application of the NNR mechanism has been validated commercially,” said J. Donald deBethizy, President and CEO of Targacept.

“Emerging science has made the promise of NNR-targeted compounds as smoking cessation aids increasingly evident. It is important for a smoking cessation aid to specifically target the areas of the brain that serve as pathways for addiction, while addressing limitations of currently available products by minimizing unwanted side effects.”

Neuronal nicotinic receptors (NNRs) are a class of proteins in the nervous system that modulate the levels of key chemical messengers, such as dopamine. Nicotine’s addictive effects have been linked to over-stimulation of dopamine release in brain regions involved in feelings of reward and pleasure.

Various NNR subtypes modulate dopamine release in these pathways and represent optimal targets for therapeutic intervention. Compounds that can normalize the activity of these NNR subtypes have the potential to decrease the rewarding effects of nicotine and, as a result, the desire to smoke.

In July 2007, Targacept and GSK entered into a strategic alliance pursuant to which Targacept would utilize its proprietary Pentad™ drug discovery technology to discover novel small molecule product candidates that target specified NNR subtypes in five therapeutic areas -- pain, smoking cessation, addiction, obesity and Parkinson’s disease. GSK is participating in the alliance through its Center of Excellence for External Drug Discovery.

Statistics from the Centers for Disease Control and Prevention indicate that tobacco use remains the leading preventable cause of death in the United States, causing approximately 438,000 premature deaths each year. Datamonitor projects that the global prescription market for smoking cessation therapies will be as much as $4.6 billion by 2016.

Advertisement